Alkermes, Avadel Pharmaceuticals merger gets HSR clearance in US
MLex Summary: The Hart-Scott-Rodino waiting period expired Monday allowing pharmaceutical company Alkermes' proposed $2.1 billion acquisition of sleep disorder treatment-maker Avadel Pharmaceuticals to move forward.Excerpt. ...To view the full article, register now.
Already a subscriber? Click here to view full article